Back to search

Switzerland· 69428003

Omjjara 200 mg, Filmtabletten

A momelotinib product containing momelotinibum, registered in Switzerland by GlaxoSmithKline AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EJ04

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedOmjjara 200 mg, FilmtablettenATCL01EJ04REGISTER NO.69428003PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Momelotinib is registered in 15 of 19 countries.

Countries holding a registration under ATC L01EJ04 (momelotinib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Momelotinib · ATC L01EJ04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of momelotinib costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $309.44 in Switzerland — a ×1929 gap.

  • Switzerland: $309.44 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Momelotinib · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$309.44
  • FR France$0.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
momelotinibum
Manufacturer
GlaxoSmithKline AG
Country
Switzerland (CH)
ATC code
L01EJ04
ATC class
Momelotinib
Defined daily dose
0.2 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680694280037
    Ds 30 Stk
    CHF 3849.4

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/25a92821-3e49-4473-aec1-7ab61d24da3d
GET /v1/drugs/25a92821-3e49-4473-aec1-7ab61d24da3d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "momelotinibum 200 mg",
  "valid_from": "2025-03-01",
  "limitations": "[{\"description\":\"Die Vergütung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nOMJJARA wird nur vergütet als Monotherapie zur Behandlung der primären Myelofibrose, der Myelofibrose nach Polycythaemia vera oder der Myelofibrose nach essentieller Thrombozythämie mit intermediärem oder hohem Risiko bei Erwachsenen mit moderater oder schwerer Anämie, die vorgängig mit Ruxolitinib behandelt wurden oder für eine Behandlung mit Ruxolitinib nicht in Frage kommen, und die nicht für eine allogene Stammzelltransplantation vorgesehen sind.<br>\\nNicht in Kombination mit Ruxolitinib.<br>\\nDie Verschreibung darf nur durch einen Facharzt für Hämatologie oder Onkologie erfolgen.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-03-01\",\"validTo\":\"2027-02-28\"}]",
  "galenic_form": "Filmtabl 200 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2025-03-01",
  "self_retention_pct": 10
}

See everything about momelotinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.